Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
Cancer Chemotherapy and Pharmacology, 06/20/2012
Ku GY et al. – The lack of benefit for cetuximab with capecitabine/bolus 5–fluorouracil (5–FU) regimens is unexpected. Cetuximab should only be used with infusional 5–FU regimens in the first–line treatment of K–ras wild–type (WT) colorectal cancer patients.